ProMed Pharma and DSM Biomedical recently announced a business development partnership focused on polymeric drug delivery. The collaboration combines ProMed’s micromolding and extrusion capabilities in conjunction with DSM’s biomedical polyurethanes, polyurethaneureas, and bioerodible amino acid-based polyesteramides. Get the full story on our sister site Medical Design & Outsourcing.
DSM
Aerie inks deal for implantable drug-delivery system
Aerie Pharmaceuticals (NSDQ:AERI) said today that it inked a collaborative R&D and licensing agreement with DSM to develop an implantable drug-delivery system for patients with glaucoma and other retinal diseases. DSM has reportedly developed an injectable drug-delivery fiber using polyesteramide polymers that has proven successful in preclinical work with Aerie’s compounds. A product candidate developed by […]
